Trial reportBMC pulmonary medicine2010
No effect of epoprostenol on right ventricular diameter in patients with acute pulmonary embolism: a randomized controlled trial.
Trial report in BMC pulmonary medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 39 citations in OpenAlex.
- Pulmonary vasodilation by sildenafil in acute intermediate-high risk pulmonary embolism: a randomized explorative trial.BMC pulmonary medicine · 2021Trial
- Randomized trial of inhaled nitric oxide to treat acute pulmonary embolism: The iNOPE trial.American heart journal · 2017Trial
- Ketone bodies for hemodynamic support in acute pulmonary embolism: a randomized, blinded, controlled animal study.Intensive care medicine experimental · 2025Article
- Non-mechanical haemodynamic support in acute pulmonary thromboembolism: a scoping review.Intensive care medicine experimental · 2025Review
- Supplemental oxygen for pulmonary embolism (SO-PE): study protocol for a mechanistic, randomised, blinded, cross-over study.BMJ open · 2024Article
- Review
- Immediate cardiopulmonary responses to consecutive pulmonary embolism: a randomized, controlled, experimental study.BMC pulmonary medicine · 2024Article
- Management of high-risk pulmonary embolism in the emergency department: A narrative review.The American journal of emergency medicine · 2024Review
- Changes in Pulmonary Vascular Resistance and Obstruction Score Following Acute Pulmonary Embolism in Pigs.Critical care explorations · 2024Article
- Hemodynamic and respiratory support in pulmonary embolism: a narrative review.Frontiers in medicine · 2023Review
- Endothelial nanomedicine for the treatment of pulmonary disease.Expert opinion on drug delivery · 2015Review
- Gas exchange and pulmonary hypertension following acute pulmonary thromboembolism: has the emperor got some new clothes yet?Pulmonary circulation · 2014Review
- Management dilemmas in acute pulmonary embolism.Thorax · 2014Review
- Losartan exerts no protective effects against acute pulmonary embolism-induced hemodynamic changes.Naunyn-Schmiedeberg's archives of pharmacology · 2012Article
- Pulmonary vasodilation in acute pulmonary embolism - a systematic review.Pulmonary circulationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRight ventricular dilatation in the setting of acute pulmonary embolism is associated with an adverse prognosis. Treatment with a pulmonary vasodilator has never been studied systematically. We evaluated the effect of epoprostenol on right ventricular diameter and function in patients with acute pulmonary embolism and right ventricular dilatation.
methodsIn a randomized, single-blind study, 14 patients with acute pulmonary embolism received epoprostenol or placebo infusion for 24 hours on top of conventional treatment. Effects on right ventricular end-diastolic diameter, systolic pulmonary artery pressure, right ventricle fractional area change and tricuspid annular plane systolic excursion were assessed by serial echocardiography. Furthermore Troponin T and NT-proBNP were measured serially.
resultsCompared to placebo, epoprostenol was associated with a relative change from baseline in right ventricular end-diastolic diameter of +2% after 2.5 hours and -8% after 24 hours. Epoprostenol did not have a significant effect on systolic pulmonary artery pressure, right ventricular fractional area change and tricuspid annular plane systolic excursion, nor on biochemical parameters.
conclusionIn patients with acute pulmonary embolism and right ventricular overload, treatment with epoprostenol did not improve right ventricular dilatation or any other measured variables of right ventricular overload.
trial registrationREGISTRATION: URL: NCT01014156Medical ethical committee: Medisch-ethische toetsingscommissie (METc) from the VUmc (free university medical centre).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.